Navigation Links
FDA Licenses First US Vaccine Against Avian Flu

Sanofi pasteur, the vaccines division of the sanofi-aventis Group has received the license from the US FDA for its H5N1 vaccine, the first avian influenza vaccine for humans in// the US. Sanofi pasteur, in collaboration with the National Institutes of Health, submitted a biologics license application to the FDA for this H5N1 vaccine. The licensure serves as a first key step in achieving the government's goal of stockpiling vaccine intended to protect those who are at increased risk of exposure to the H5N1 influenza virus contained in the vaccine during the early stages of a pandemic.

"The licensure of the nation's first vaccine is a significant milestone in pandemic preparedness," said David Williams, President, Chairman and Chief Executive Officer of sanofi pasteur. "As the leading manufacturer of influenza vaccine in the world and a longstanding, responsible member of the immunization community, we will play a key role in helping safeguard human health if an influenza pandemic strikes. We look forward to continuing to work with the US government and others, to prepare for this crisis."

The licensure of this vaccine was based on a clinical trial conducted by the National Institute of Allergy and Infectious Diseases. This trial evaluated the safety and ability to generate an immune response of this vaccine when administered in two 90-ug/ml doses in healthy adults 18 through 64 years. The study, which was completed in 2005, showed that the vaccine elicited an immune response against the H5N1 virus and was associated with mild side effects.

As the world leader in research, development and manufacturing of influenza vaccines, sanofi pasteur is actively involved in pandemic preparedness. Sanofi pasteur is committed to continuing its robust research and development program by exploring strategies for protecting more people, including the evaluation of new adjuvants; the use of cell culture production processes; and assessing the ability of vaccine formulations to generate immune responses against other strains of the H5N1 virus. Additionally, sanofi pasteur has invested in a major expansion of its influenza vaccine production capacity in both the US and France.

Source-BioSpectrum/V
'"/>




Related medicine news :

1. US Government Licenses New Hypertension Drug
2. Panacea Biotec In-Licenses FMD Vaccine
3. Thailand Goes Ahead With Licenses for Generic Drugs
4. Swedish Biotech Licenses HIV Drug to China for Development
5. More Foreign Trained Doctors Receive Licenses
6. First Vaccine Designed for Africa Cleared for Testing in Humans
7. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
8. First human clone is near
9. First Artificial Heart patient has Major setback
10. First head-to-head trials of once weekly Fosamax and Actonel therapies
11. WHO Declares Vietnam First Country to Control SARS
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/29/2017)... , ... March 29, 2017 , ... ... with or without a referral to new patients from Burnaby, BC. Patients in ... other full mouth reconstruction services, can see the esteemed team at Wall Centre ...
(Date:3/29/2017)... ARBOR, Mich. (PRWEB) , ... ... ... Retailer and Manufacturer Alliance (GRMA) is growing as it continues developing an ... dietary supplement industry. The organization, which plans to publish the first ANSI-approved ...
(Date:3/29/2017)... ... March 29, 2017 , ... An inventor from Raynham, ... bands used in conjunction with my braces always rubbed against the inside of ... to prevent this problem." The O.B.S. was the result of his brainstorming. , ...
(Date:3/29/2017)... ... 29, 2017 , ... Hamlin Dental Group, multi-location dental office in North ... Dental lasers are safe and effective options, and can be used alone or in ... overall quality of care. , Dr. Hamid Reza of Hamlin Dental Group offers other ...
(Date:3/29/2017)... ... March 29, 2017 , ... AvePoint , the Microsoft Cloud ... location in Richmond, Virginia, located at the Riverfront Plaza, 901 East Byrd Street. AvePoint ... of Virginia Ralph S. Northam and Mayor of Richmond Levar M. Stoney. , Founded ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Research and Markets has announced the addition of the "Global ... ... market to grow at a CAGR of 2.87% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:3/29/2017)... March 29, 2017  Spiral Therapeutics, Inc. today ... Bionure Farma, S.L. for the worldwide exclusive rights ... in the field of otolaryngology for aggregate payments ... The agreement provides Spiral with the option ... differentiated product profile. Under the terms of the ...
(Date:3/29/2017)... -- NetworkNewsWire Editorial Coverage  ... There are a number of ... but economic arguments also favor its legalization. The benefits include ... However, to legalize and regulate marijuana requires an ecosystem of ... ( SING Profile ), American Cannabis Company (OTC: AMMJ), Kush ...
Breaking Medicine Technology: